<DOC>
	<DOCNO>NCT02569307</DOCNO>
	<brief_summary>This randomize double-blind placebo control trial aim evaluate efficacy tolerability minocycline Omega-3 fatty acid patient ARMS . Specifically determine whether addition minocycline / Omega-3 fatty acid Treatment Usual operationalized ARMS population Pakistan :</brief_summary>
	<brief_title>Minocycline and/or Omega-3 Fatty Acids Added Treatment Usual At Risk Mental States</brief_title>
	<detailed_description>Primary hypothesis person ARMS prescribed minocycline / Omega-3 fatty acid reduce transition rate psychosis one year follow period ( baseline ) compare Treatment-As-Usual ( TAU ) . The transition rate lowest group receive minocycline Omega-3 fatty acid combination . Secondary objective determine Persons ARMS prescribed minocycline / Omega-3fatty acid combination great symptom reduction compare TAU . This study six-month intervention minocycline and/or Omega-3 fatty acid add TAU patient ARMS , use randomise , placebo-controlled , double-blind factorial design.The study four-arm trial : one arm receive minocycline TAU ; second arm receive Omega-3 fatty acid TAU ; third arm receive minocycline Omega-3 fatty acid TAU ; fourth arm receive placebo TAU .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Male female help seek individual age 1635 year . 2 . Meets least one criterion ARMS ( see CAARMS Operationalized Intake Criteria section ) . 3 . Assessed competent provide inform consent . 1 . History ofpreviously experience psychotic illness ( treat untreated ) . 2 . IQ &lt; 70 and/or history learn disability . 3 . Any preexisting inflammatory condition e.g . rheumatoid arthritis . 4 . Organic brain disease e.g . epilepsy . 5. treatment antipsychotic moodstabilising agent . 6 . Prior history intolerance serious side effect ( hepatotoxicity , photosensitivity , blood dyscrasia ) tetracyclines Omega3 fatty acid . 7 . Concomitant penicillin therapy concomitant anticoagulant therapy . 8 . Active substance abuse ( except nicotine caffeine ) dependence within last three month , accord DSMV criterion . 9 . Treatment warfarin lamotrigine . 10 . Current previous treatment tetracycline antibiotic Omega3 fatty acid precede three month study entry . 11 . Current treatment antiinflammatory medication . 12 . Treatment electroconvulsive therapy within 12 week precede study . 13 . Active expression suicidal ideation ( CAARMS item 7.3 severity score 6 ) current aggression/dangerous behaviour ( CAARMS item 5.4 severity score 6 ) . 14 . Relevant current past hematologic , hepatic , renal , neurological medical disorder opinion principal investigator may interfere study . 15 . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>At Risk Mental State</keyword>
	<keyword>Prodromal Phase</keyword>
	<keyword>Psychosis</keyword>
</DOC>